Pelthos Reports Q3 2026 Earnings with Significant Zelsuvmi Revenue Growth and Narrowing Net Loss
Pelthos (PTHS) reported strong third-quarter 2026 financial results, highlighted by a 114% year-over-year increase in Zelsuvmi net product revenue to $15.2 million. The growth was driven by increased utilization and strategic gross-to-net optimizations following a major agreement with a Pharmacy Benefit Manager that expanded commercial coverage to approximately 69% of the market. The company significantly improved its bottom line, reporting a net loss of $7.9 million compared to a $23.4 million loss in the previous quarter. This improvement was aided by a 25% decrease in SG&A expenses and a 39% reduction in per-unit cost of goods sold. While adjusted EBITDA remains negative at $5.6 million, management is focusing on scaling Zelsuvmi while preparing for upcoming product launches including Xepi and Xeglyze.
Tickers: $PTHS
Topics: cost reduction market coverage product performance revenue growth